Mowi ASA (OSE:MOWI): Presentation of Q1 2025 results 14 May 2025 at 08:00 (CET)

May 5, 2025

Mowi ASA hereby invites you to the presentation of the results for the first quarter 2025 at Hotel Continental, Stortingsgaten 24/26, 0117 Oslo, Norway.

The results will be presented in English through a live webcast followed by a Q&A session. Participants will have the opportunity to submit questions online throughout the webcast session. The webcast will be available on http://www.mowi.com/investors/reports/

A recording of the webcast will be made available on our website immediately afterwards.

Please note that the quarterly report and presentation will be published at 06:30 (CET).

This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Scorpius Holdings Announces Corporate Update Including Cost Optimization Initiatives, Strategic Corporate Developments, and Potential Opportunities for Expansion into Southeast Asia

Contract for financing the construction of the final stage of the Uus-Järveküla residential area and profit distribution to fund investors

Mowi ASA (OSE:MOWI): Presentation of Q1 2025 results 14 May 2025 at 08:00 (CET)

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Implementation of capital reduction

Hazer and KBR Enter Global Deal to Accelerate Licensing and Commercialisation

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Creative Realities, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information

Topics

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Implementation of capital reduction

Hazer and KBR Enter Global Deal to Accelerate Licensing and Commercialisation

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Creative Realities, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information

Palvella Therapeutics to Ring the Nasdaq Opening Bell on May 12, 2025

SunHydrogen Contracts The Process Group for Front-End Engineering Design of 25m2 Renewable Hydrogen Pilot Plant

SEALSQ’s VaultIC 408 Meets FIPS 140-3 Requirements, Advancing NIST Certification and Strengthening Leadership in Secure IoT and Smart Grid Solutions

Related Articles

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Implementation of capital reduction

Hazer and KBR Enter Global Deal to Accelerate Licensing and Commercialisation

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Creative Realities, Inc. Announces First Quarter 2025 Earnings Release Date and Conference Call Information

Company

Headlines

Firefly Neuroscience Achieves Multi-Fold Database, IP Portfolio, and Commercial Footprint Expansion Through Acquisition of Evoke Neuroscience, Inc.

Implementation of capital reduction

Hazer and KBR Enter Global Deal to Accelerate Licensing and Commercialisation

Alterity Therapeutics Granted U.S. FDA Fast Track Designation for ATH434 to Treat Multiple System Atrophy

Newsletter